Disparate clinicopathological correlations of p53 and Bcl-2 in colorectal cancer

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 377-382

  Papagiorgis, Petros C ^a   Zizi, Adamantia E ^b   Tseleni, Sophia ^c   Oikonomakis, Ioannis N ^d   Sofras, Leonidas ^e   Patsouris, Efstratios ^c   Nikiteas, Nikolaos I ^c  

^a ATHENS MEDICAL CENTER   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^e Panagia Odigitria General Clinic   (Greece)

Author keywords

Bcl 2; Colorectal cancer; Grade; p53; Stage

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CANCER STAGING; COLORECTAL CANCER; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROTEIN EXPRESSION;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855685291     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.687     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 6: 759-767, 1990.
3. Lengauer C, Kinzler K and Vogelstein B: Genetic instabilities in human cancers. Nature 396: 643-649, 1998. (Pubitemid 29003936)
4. Baker SJ, Markowitz S, Fearon ER, Wilson JK and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
5. Harris CC: Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-1455, 1996.
6. Koornstra JJ, De Jong S, Holema H, et al: Changes in apoptosis during the development of colorectal cancer; a systematic review of the literature. Crit Rev Oncol Hematol 45: 37-53, 2003. (Pubitemid 35449787)
7. Kaklamanis L, Savage A, Montensen N, et al: Early expression of Bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 179: 10-14, 1996. (Pubitemid 26180080)
8. Baretton G, Diebold J, Christoforis G, et al: Apoptosis and immunohistochemical Bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77: 255-264, 1996.
9. Garrity M, Burgart L, Mahoney M, et al: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair and p53 overexpression in patients with Dukes B2 or C colon cancer. J Clin Oncol 22: 1572-1582, 2004. (Pubitemid 41079794)
10. Iacopetta B: TP53 mutation in colorectal cancer. Hum Mut 21: 271-276, 2003.
11. Russo A, Bazan V, Iacopetta D, Kerr D, Soussi T and Gebbia N: The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23: 7518-7528, 2005. (Pubitemid 46291815)
12. Buglioni S, D'Agnano I, Cosimeli M, et al: Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and Bcl-2. Int J Cancer 84: 545-552, 1999.
13. Krajewska M, Kim H, Kim C, et al: Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities of new prognostic biomarkers. Clin Cancer Res 11: 5451-5461, 2005. (Pubitemid 41060821)
14. Klump B, Nehls O, Okech T, et al: Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis 19: 23-42, 2004. (Pubitemid 38088282)
15. Graziano F and Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes B colorectal cancer patients; how much evidence is enough? Ann Oncol 14: 1026-1038, 2003. (Pubitemid 36950166)
16. Tejpar S: The use of molecular markers in the diagnosis and treatment of colorectal cancer. Best Pract Res Clin Gastroenterol 21: 1071-1087, 2007.
17. Han SH, Park YM and Hwang TS: Differential expression of Bcl-2, Bcl- XL and p53 in colorectal cancer. J Gastroenterol Hepatol 21: 1108-1114, 2006.
18. Mulder J, Baas I, Polak M, Goodman S and Offerhaus G: Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 71: 1257-1262, 1995.
19. Biden K, Simms L, Cummings M, et al: Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. Oncogene 18: 1245-1249, 1999. (Pubitemid 29085998)
20. Fernadez-Cebrian J, Nevado Santos M, Vorwald Kuborn P, et al: Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker exression? Clin Transl Oncol 9: 663-670, 2007.
21. Hilska M, Collan Y, Laine VJO, Kossi J, Hirsimaki P, Laato M and Roberts PJ: The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 48: 2197-2208, 2005. (Pubitemid 43074439)
22. Leslie A, Carey FA, Pratt N, et al: The colorectal adenoma-carcinoma sequence. Br J Surg 89: 845-860, 2002. (Pubitemid 34779568)
23. Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y and Miyazaki I: p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68: 399-402, 1993. (Pubitemid 23229445)
24. Kastrinakis WV, Ramchurren N, Rieger KM, Hest DT, Loda M, Steel G and Summerhayes IC: Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11: 647-652, 1995.
25. Saleh H, Jackson H and Banerjee M: Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol 8: 175-182, 2000.
26. Chatla C, Jhala N, Katkoori V, Alexander D, Meleth S, Grizzle W and Manne U: Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. Cancer Biomark 1: 241-250, 2005.
27. Nehls O, Okech T, Hsieh C-J, et al: Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 96: 1409-1418, 2007.
28. Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50: 113-130, 2007.
29. Galizia G, Lieto E, Ferraraccio F, et al: Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10: 3490-3499, 2004. (Pubitemid 38685457)
30. Zlobec I, Steele R, Michel R, Compton C, Lugli A and Jass J: Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer. Mod Pathol 19: 1236-1242, 2006. (Pubitemid 44268194)
31. Poincloux L, Durando X, Seitz J, et al: Loss of Bcl-2 expression in colon cancer: A prognostic factor for recurrence in stage II colon cancer. Surg Oncol 18: 357-365, 2009.
32. Ilyas M, Hao X-P, Wilkinson K, et al: Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 43: 383-387, 1998. (Pubitemid 28414920)